Nasic (Xylometazoline Hydrochloride, Dexpanthenol)

Xylometazoline Hydrochloride is a selective alpha‑2 adrenergic receptor agonist. By binding to these receptors on the nasal blood vessels, it triggers vasoconstriction, which reduces swelling of the nasal mucosa and opens the airway. This rapid decongestant effect eases breathing during upper‑respiratory infections.

The exact dosing regimen for Nasic is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical judgment. Typically, the label advises a limited number of sprays per nostril, but the prescriber sets the final instructions.

Safety data for Nasic in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nasic combines a potent alpha‑adrenergic agonist (Xylometazoline) with Dexpanthenol, which promotes mucosal repair. Compared with single‑ingredient decongestants, Nasic may offer added soothing and healing benefits, while still providing rapid relief. However, clinical choice depends on individual patient needs and physician preference.

Nasic should be stored at room temperature, ideally below 25 °C. Keep the spray bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Nasic is administered as a nasal spray. The user gently inserts the nozzle into one nostril, inhales gently, and actuates the pump to deliver the recommended number of sprays. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include heavy nosebleeds, severe allergic reactions such as rash or angioedema, paradoxical worsening of congestion (rebound effect) with prolonged use, and nasal ulceration or perforation. Any signs of these reactions require immediate medical attention.

Nasic should be avoided in children younger than 2 years, individuals with known hypersensitivity to Xylometazoline, Dexpanthenol, or any excipients, and patients with severe nasal septum deviation, recent nasal surgery, or chronic nasal conditions unless advised by a physician.